365 related articles for article (PubMed ID: 28024718)
1. Patterns of dysphagia and acute toxicities in patients with head and neck cancer undergoing helical IMRT±concurrent chemotherapy.
Moroney LB; Helios J; Ward EC; Crombie J; Wockner LF; Burns CL; Spurgin AL; Blake C; Kenny L; Hughes BG
Oral Oncol; 2017 Jan; 64():1-8. PubMed ID: 28024718
[TBL] [Abstract][Full Text] [Related]
2. Helical intensity-modulated radiotherapy with concurrent chemotherapy for oropharyngeal squamous cell carcinoma: A prospective investigation of acute swallowing and toxicity patterns.
Moroney LB; Helios J; Ward EC; Crombie J; Pelecanos A; Burns CL; Spurgin AL; Blake C; Kenny L; Chua B; Hughes BGM
Head Neck; 2018 Sep; 40(9):1955-1966. PubMed ID: 29756244
[TBL] [Abstract][Full Text] [Related]
3. Enteral nutrition support and treatment toxicities in patients with head and neck cancer receiving definitive or adjuvant helical intensity-modulated radiotherapy with concurrent chemotherapy.
Blake CL; Brown TE; Pelecanos A; Moroney LB; Helios J; Hughes BGM; Chua B; Kenny LM
Head Neck; 2023 Feb; 45(2):417-430. PubMed ID: 36433667
[TBL] [Abstract][Full Text] [Related]
4. Radiotherapy for cutaneous head and neck cancer and parotid tumours: a prospective investigation of treatment-related acute swallowing and toxicity patterns.
Moroney LB; Helios J; Ward EC; Crombie J; Burns CL; Yeo SQ; Pelecanos A; Spurgin AL; Blake C; Kenny L; Chua B; Hughes BGM
Support Care Cancer; 2019 Feb; 27(2):573-581. PubMed ID: 30019149
[TBL] [Abstract][Full Text] [Related]
5. Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma.
Thomson DJ; Ho KF; Ashcroft L; Denton K; Betts G; Mais KL; Garcez K; Yap BK; Lee LW; Sykes AJ; Rowbottom CG; Slevin NJ
Acta Oncol; 2015 Jan; 54(1):88-98. PubMed ID: 25279959
[TBL] [Abstract][Full Text] [Related]
6. Acute hematologic and mucosal toxicities in head and neck cancer patients undergoing chemoradiotherapy: a comparison of 3D-CRT, IMRT, and helical tomotherapy.
Kruser TJ; Rice SR; Cleary KP; Geye HM; Tome WA; Harari PM; Kozak KR
Technol Cancer Res Treat; 2013 Oct; 12(5):383-9. PubMed ID: 23547974
[TBL] [Abstract][Full Text] [Related]
7. Favourable impact of intensity-modulated radiation therapy on chronic dysphagia in patients with head and neck cancer.
Anand AK; Chaudhoory AR; Shukla A; Negi PS; Sinha SN; Babu AA; Munjal RK; Dewan AK; Kumar K; Doval DC; Vaid AK
Br J Radiol; 2008 Nov; 81(971):865-71. PubMed ID: 18941046
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Acute Toxicities, Overall Treatment Time and Quality of Life in Head and Neck Cancer Patients Treated with IMRT and Helical Tomotherapy.
R YB; Swamy K; Swaroopa C; Maiya V
Gulf J Oncolog; 2024 May; 1(45):7-14. PubMed ID: 38774928
[TBL] [Abstract][Full Text] [Related]
9. Practical considerations in reducing swallowing dysfunction following concurrent chemoradiotherapy with intensity-modulated radiotherapy for head and neck cancer.
Batth SS; Caudell JJ; Chen AM
Head Neck; 2014 Feb; 36(2):291-8. PubMed ID: 23508721
[TBL] [Abstract][Full Text] [Related]
10. Nutrition outcomes and treatment toxicities in patients with head and neck cancer receiving helical intensity-modulated radiotherapy.
Blake C; Lai R; Brown T; Pelecanos A; Moroney L; Helios J; Smith D; Hughes BGM; Kenny L; Chua B; Bauer J
J Hum Nutr Diet; 2024 Feb; 37(1):182-192. PubMed ID: 37737485
[TBL] [Abstract][Full Text] [Related]
11. Acute symptoms during the course of head and neck radiotherapy or chemoradiation are strong predictors of late dysphagia.
van der Laan HP; Bijl HP; Steenbakkers RJ; van der Schaaf A; Chouvalova O; Vemer-van den Hoek JG; Gawryszuk A; van der Laan BF; Oosting SF; Roodenburg JL; Wopken K; Langendijk JA
Radiother Oncol; 2015 Apr; 115(1):56-62. PubMed ID: 25792467
[TBL] [Abstract][Full Text] [Related]
12. DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer.
Petkar I; Rooney K; Roe JW; Patterson JM; Bernstein D; Tyler JM; Emson MA; Morden JP; Mertens K; Miles E; Beasley M; Roques T; Bhide SA; Newbold KL; Harrington KJ; Hall E; Nutting CM
BMC Cancer; 2016 Oct; 16(1):770. PubMed ID: 27716125
[TBL] [Abstract][Full Text] [Related]
13. Late dysphagia after IMRT for head and neck cancer and correlation with dose-volume parameters.
Mortensen HR; Jensen K; Aksglæde K; Behrens M; Grau C
Radiother Oncol; 2013 Jun; 107(3):288-94. PubMed ID: 23791365
[TBL] [Abstract][Full Text] [Related]
14. Prospective evaluation of Intensity Modulated Radiation Therapy with Simultaneous Integrated Boost (IMRT-SIB) in head and neck squamous cell carcinoma in patients not suitable for chemo-radiotherapy.
Rastogi M; Sapru S; Gupta P; Gandhi AK; Mishra SP; Srivastava AK; Khurana R; Hadi R; Sahni K; S F
Oral Oncol; 2017 Apr; 67():10-16. PubMed ID: 28351562
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of response of oral and pharyngeal mucosa in patients receiving chemo-IMRT for head and neck cancer using hypofractionated accelerated radiotherapy.
Bhide SA; Gulliford S; Fowler J; Rosenfelder N; Newbold K; Harrington KJ; Nutting CM
Radiother Oncol; 2010 Oct; 97(1):86-91. PubMed ID: 20826031
[TBL] [Abstract][Full Text] [Related]
16. A prospective, comparative analysis of acute toxicity profile between three-dimensional conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT) in locally advanced head and neck cancer patients.
Kucha N; Soni TP; Jakhotia N; Patni N; Singh DK; Gupta AK; Sharma LM; Goyal J
Cancer Treat Res Commun; 2020; 25():100223. PubMed ID: 33120316
[TBL] [Abstract][Full Text] [Related]
17. IMRT-SIB with concurrent and neo-adjuvant platinum-based chemotherapy for locally advanced head and neck squamous cell cancer: analysis of clinical outcomes in a retrospective series of a single institution.
Mazzeo E; Antognoni P; Parmiggiani M; D'Ambrosio C; De Marco G; Marra L; Gottardi G; Bertoni F
Tumori; 2014; 100(6):652-9. PubMed ID: 25688499
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer.
Guerrero Urbano T; Clark CH; Hansen VN; Adams EJ; A'Hern R; Miles EA; McNair H; Bidmead M; Warrington AP; Dearnaley DP; Harrington KJ; Nutting CM
Radiother Oncol; 2007 Oct; 85(1):36-41. PubMed ID: 17709149
[TBL] [Abstract][Full Text] [Related]
19. Physical and Radiobiological Evaluation of Accelerated Intensity Modulated Radiotherapy for Locally Advanced Head and Neck Cancer and Comparison with Short-Term Clinical Outcomes.
Buchapudi RR; Manickam R; M R AK; C R TP; Chandraraj V; Pyakuryal A; Narayanasamy G
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2463-2470. PubMed ID: 31450921
[TBL] [Abstract][Full Text] [Related]
20. Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial.
Nutting C; Finneran L; Roe J; Sydenham MA; Beasley M; Bhide S; Boon C; Cook A; De Winton E; Emson M; Foran B; Frogley R; Petkar I; Pettit L; Rooney K; Roques T; Srinivasan D; Tyler J; Hall E;
Lancet Oncol; 2023 Aug; 24(8):868-880. PubMed ID: 37423227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
